{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-130017","form_type":"8-K","ticker":"QNRX","cik":"0001671502","company_name":"Quoin Pharmaceuticals, Ltd.","filed_at":"2024-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.175931+00:00","generated_at":"2026-05-29T01:41:47.551821+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Quoin Pharma gets FDA clearance for whole-body QRX003 study in Netherton Syndrome","bullets":["FDA clearance for new Netherton Syndrome study of QRX003 applied to >80% BSA twice daily for 12 weeks in up to 8 patients.","Prior studies used ~20% BSA; new whole-body design mimics real-world use to support potential regulatory approval.","Study led by Dr. Amy Paller at Northwestern University; data to supplement QRX003 NDA package.","Quoin is a clinical-stage specialty pharma focused on rare/orphan diseases; stock trades as QNRX."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-130017","json":"https://secwatch.observer/filing/0001104659-24-130017.json","markdown":"https://secwatch.observer/filing/0001104659-24-130017.md","text":"https://secwatch.observer/filing/0001104659-24-130017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671502/000110465924130017/0001104659-24-130017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671502/000110465924130017/tm2431545d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T01:41:47.551821+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}